GASTROESOPHAGEAL ADENOCARCINOMA
Clinical trials for GASTROESOPHAGEAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cancer drug TAK-500 tested in 61 patients – study halted early
Disease control TerminatedThis early-phase trial tested an experimental drug called TAK-500, alone or with the immunotherapy pembrolizumab, in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The stud…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental radioactive therapy targets Hard-to-Treat cancers
Disease control TerminatedThis early-stage study tested a radioactive drug called 177Lu-FF58 in 24 people with advanced pancreatic, gastroesophageal, or brain cancer. The drug seeks out and attaches to specific proteins on cancer cells to deliver radiation directly. The main goals were to check safety, fi…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New imaging agent aims to spot Hard-to-Find cancers
Diagnosis TerminatedThis early-phase trial tested a radioactive imaging agent called 68Ga-FF58 in 14 adults with certain advanced solid tumors (glioblastoma, brain metastases from breast cancer, gastroesophageal cancer, or pancreatic cancer). The goal was to see if the agent could help detect these …
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated Jun 27, 2026 07:54 UTC